Peter Schmid becomes Redcare Pharmacy CEO. Redcare Pharmacy stock gains 1.98 percent
Published on 10/14/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership and growth figures
- Peter Schmid von Linstow became CEO on October 14, 2026.
- Redcare Pharmacy raised fiscal 2026 total revenue growth guidance to 16 to 18 percent on September 28, 2026.
- Redcare Pharmacy stock trades at EUR 71.95 at 12:45 p.m. CEST at Lang & Schwarz on October 14, 2026, 1.98 percent above the Xetra close of October 13, 2026.
Redcare Pharmacy (NL0012044747) was trading at EUR 71.95 at Lang & Schwarz on October 14, 2026, at 12:45 p.m. CEST, 1.98 percent above the Xetra close of October 13, 2026, at EUR 70.55. According to MarketScreener on October 14, 2026, Peter Schmid von Linstow was appointed to the managing board and became chief executive officer.
Three events reshape the story
On September 28, 2026, Redcare Pharmacy raised its fiscal 2026 total revenue growth guidance to 16 to 18 percent from 15 to 17 percent. The company also lifted its German prescription revenue target to EUR 730 million to EUR 760 million from EUR 680 million to EUR 720 million, while preliminary prescription revenue growth reached 56 percent in the third quarter.
On October 5, 2026, EQS News reported that a Redcare study examined 49 critical medicines across six European countries. The sequence points to a business increasingly tied to prescription demand, while the leadership change adds a new execution test.
On October 14, 2026, the CEO appointment became the latest dated company event. Schmid brings more than 20 years of leadership experience at digital platforms and marketplaces, including Visable, eBay and AutoScout24, according to MarketScreener.
What does the CEO change mean?
The immediate test is profitable scaling. Redcare's fiscal 2026 outlook calls for 16 to 18 percent total revenue growth, while adjusted EBITDA margin guidance remains 2.5 to 3.0 percent, according to the September 28 company release.
That combination gives the stock a measurable operating hurdle: prescription growth must support both the EUR 730 million to EUR 760 million German revenue target and the unchanged margin range. The new CEO's platform background is therefore relevant to execution, but the next report will provide the first fresh operating checkpoint.
Upcoming reporting dates
Redcare Pharmacy lists its third-quarter 2026 interim statement for October 29, 2026, followed by a Baader Bank investor event on November 2, 2026, on its investor-relations calendar at Redcare Pharmacy. Those dates put the next results release ahead of the first full quarter under the new CEO.
Stock trades above the Xetra close
At 12:45 p.m. CEST on October 14, 2026, Redcare Pharmacy was trading at EUR 71.95 at Lang & Schwarz, 1.98 percent above the Xetra close of October 13, 2026, at EUR 70.55. The stock remains EUR 17.55 below the finance-data 52-week high of EUR 89.50 and EUR 41.75 above the low of EUR 30.20, both dated October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy at a glance
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- WKN: A2AR94
- Ticker: RDC
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 14, 2026, 12:45 p.m. CEST): EUR 71.95
- Change versus Xetra close: plus 1.98 percent
- Xetra close (October 13, 2026): EUR 70.55
- Market capitalization: EUR 1.4 billion (as of October 14, 2026)
- 52-week range: EUR 30.20-89.50 (as of October 14, 2026)
- Sector / Industry: Healthcare / Medical - Distribution
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report DAX.
